126 results about "Toxoplasmosis" patented technology

Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii (T. gondii) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula,

wherein the variables X, Y, Z, L, R¹, and R³ are defined herein.

The invention relates to a soluble powder for treating livestock and poultry bacterial infection and parasitosis, comprising nortloxacin lactate, trimethoprim and auxiliary materials, the medicament of the invention is taken as antibiotic medicament, is mainly used for treating various diseases and parasitosis caused by sensitive bacterias, has better curative effects for pig toxoplasmosis, pig hydropsy, poultry, rabbit coccidiosis, the nortloxacin lactate and the trimethoprim are compatible with each other for using and generating cooperating action, the medicament of the invention has excellent oral administration absorption effect and high safety.

The invention provides polypeptide fragments derived from TgAMA-1, nucleic acids that encode the polypeptide fragments, and TgAMA-binding polypeptides such as antibodies. Methods for using the polypeptide and nucleic acid molecules to produce vaccines are also provided. In addition the invention provides methods involving use of the polypeptides, nucleic acids, and binding polypeptides, such as antibodies, for the prevention and treatment of Toxoplasmosis.

The invention relates to a formula of a medicament for treating swine high fever and a using method thereof. The medicament is prepared by dissolving 0.5 to 25 percent of Chinese angelica extract, 0.5 to 25 percent of rhubarb extract, 0.5 to 25 percent of Himalayan teasel root extract, 0.5 to 25 percent of common clubmoss herb extract, 0.5 to 25 percent of liquorice root extract, 0.5 to 25 percent of croton seed extract, 0.5 to 25 percent of toad venom, 0.5 to 25 percent of cicada slough extract, 0.5 to 25 percent of radix scutellariae extract, 0.5 to 25 percent of honeysuckle extract and 0.5 to 25 percent of common andrographis herb extract with solvent normal saline to obtain an injection, wherein the sum of the components and the balance is one hundred percent. The medicament has special effects on early and middle high fever, fulminant epidemic diseases from 2006 to 2009, mixed epidemic swine fever blue-eared disease of virus, pathogenic bacteria and worm, pseudorabies, blood worm, toxoplasmosis, lung plague, erysipelas, eircovims, streptococcus, haemophilus diseases, pneumonia, bronchitis and abdominal respiration and can relieve nose and mouth foaming in two hours.

The invention discloses a PCR detection reagent box of animal toxoplasmosis; the box contains DNA lysate, red blood cell lysate, white blood cell lysate, PCR reaction liquid and toxoplasmosis gene DNA positive control liquid; the 529bp repeated DNA segment of toxoplasmin is taken as genetic mark and special primer is taken to optimize the PCR reaction conditions such as the magnesium ion consistency, the anneal temperature and the regulation of the cycle number. The invention can detect the toxoplasmosis infection of pig, dog and cat in a fast special sensible way; the operation is convenient and the sensibility is high; the invention can be used for diagnosing the toxoplasmosis of pig, dog and cat and detecting and testing the drug effect appraisal of the selection of the toxoplasmosis medicines.

The invention discloses a compound sodium sulfadimidine injection liquid for a pig and a preparation method thereof, aiming at providing a compound kanamycin sulfate injection liquid which has fast effect for treating toxoplasmosis of the pig, addresses both the symptoms and root causes, reduces the time and dosage of used drug and has convenient drug usage, and a preparation method with simple technique and easy implementation. Each 100L injection liquid comprises: 5 to 20 sodium sulfadimidine, 1 to 10kg of lincomycin hydrochloride, 5 to 20kg of doxofylline, 1 to 4kg of trimethoprim, 0.2kg of sodium bisulfite, 0.01kg of EDTA-2Na, 40kg of propylene glycol, 10kg of 95% alcohol and the balance of water for injection. The injection liquid has fast effect for toxoplasmosis of the pig, addresses both the symptoms and root causes, can effectively treat and prevent secondary infection of bacterium, reduces drug resistance of pathogenic microorganism and leads the pig to accelerate restoring. Simultaneously, the compound sodium sulfadimidine injection liquid is an injection liquid and has convenient use.

Uracil auxotroph mutants of apicomplexans are provided which lack a functional carbamoyl phosphate synthase II (CPSII) enzyme. Also provided are T. gondii autoxtroph mutants which express exogenous antigens, and methods of protecting an animal against a T. gondii and non-T. gondii disease.

The invention discloses a compound sulphamethoxazole injection and a preparation method thereof. The injection is prepared from 5-20 % of the main drug sulphamethoxazole, 2-10 % of flunixin meglumine, 1-4 % of trimethoprim, 0.2-0.4 % of an accessory anti-oxidant, 40-70 % of an organic solvent, 0.5-2 % of an adjusting reagent and the balance being water for injection. The injection prepared by the invention can provide effective treatment for secondary infections and mixed infections of streptococcus diseases, toxoplasmosis, eperythrozoonosis, E. coli diseases, asthma and other diseases, is obvious in long-term effects, with a drug effect being enhanced by several times to dozens of times, small in application amount, few in drug using times, little in irritation and fast in performance of drug effects, saves production cost, increases added value of products, and reduces toxic and side effects due to drug mismatch during treatment.

The present invention belongs to the field of biotechnology, and relates to a surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment, encoded gene and use thereof. According to the invention, the surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment is filtered from a base through establishing a Toxoplasma gondii human immunoglobulin, ELISA, diluting the prothrombin time, sequencing analysis, etc. Through expression purifying and authenticating, the human antigen Fab fragment is authenticated to specifically identify the tachyzoite-bradyzoite recombination SAG1 of Toxoplasma gondii and have higher affinity with the tachyzoite-bradyzoite recombination SAG1 of Toxoplasma gondii, for being identified with the specificity of Toxoplasma gondii tachyzoite-bradyzoite. The human antigen Fab fragment of the invention does not contain Fc segment and does not activate the alexin or cause the histopathological damages of human immune response, etc. when the function of restricting the invasion of Toxoplasma gondii to the host cell is exerted. The surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment is safe and reliable when applied for the human body. The antigen medicine for treating toxoplasmosis or the antigen targeted medicine can be prepared.

The invention provides a Chinese medicinal composition for prevention of toxoplasmosis. Being a medicine for oral administration, the Chinese medicinal composition contains five Chinese herbal medicines: sophora flavescens, phellodendron, polygonum cuspidatum, raw hawthorn, and Magnolia officinalis. The Chinese medicinal composition is applicable to toxoplasmosis in human and animals, can be decocted in water and then used directly, and also can be prepared into oral liquids, tablets and other orally taken drugs for clinical use. Drugs prepared according to the prescription involved in the invention can achieve good effects and are cheap in price.

The invention relates to a drug combined health-care mosquito incense for livestock. The mosquito incense provided by the invention is prepared by the following steps of: weighing pharmaceutical materials of herba schizonepetae, radix sileris, platycodon root, mint, liquorice, folium artemisiae argyi, honeysuckle and rhizoma coptidis according to a reasonable proportion, removing impurities, washing and drying in the sun, mixing the pharmaceutical materials with high-quality carbon, corncob and a synergist (such as piperonyl butoxide, asarinin, SVI and propylisome) according to a reasonable proportion, grinding into fine powders of 100-200 meshes, mixing the fine powders, fully and uniformly stirring, moulding, spraying an appropriate proportion of cyfluthrin, drying, sealing with a plastic film, packaging, warehousing, and selling or storing for standby. The mosquito incense is ignited for fumigating an animal house so as to expel flies and mosquitoes, Simuliidae and Culicoides in summer, inhibit bacteria, change smell in the animal house and purify the environment. Therefore, dissemination medium is cut out, and simultaneously mycoplasma suis, toxoplasmosis, leucocytozoosis and the like are also prevented. The mosquito incense provide by the invention has advantages of wide drug effect range, big smoke and long combustion time (10-12 hours), is nontoxic, has no side effect, and is convenient and fast to use.

The invention relates to a feed additive for preventing and treating swine toxoplasmosis. The feed additive comprises the following components: honeysuckle, radix sophorae flavescentis, radix polygonati officinalis, cowherb seed, sage, poria cocos, mirabilite, crude dragon bone, polygala tenuifolia, coptis chinensis, radix bupleuri, mangnolia officinalis, patrinavillosajuss, sculellaria barbata, radix angelicae pubescentis, sanguisorba officinalis and scorpio. The feed additive for preventing and treating swine toxoplasmosis provided by the invention adopts a traditional Chinese medicine preparation; the swine toxoplasmosis can be effectively prevented and treated; the disease resistance of the pig is improved; the morbidity of the pig in the growth process is reduced; the growth speed of the pig is improved; the feed additive is prepared from traditional Chinese medicine components, and is free of residual toxicity; and the pork quality can be improved.

The invention discloses a DNA vaccine for preventing toxoplasmosis of humans or animals. An ROP19 gene is amplified through PCR, the amplified ROP19 gene is inserted into a eukaryotic expression vector pEGFP-C1 to build recombinant plasmid pEGFP-C1-ROP19 (pROP19), the recombinant plasmid containing a target gene is extracted, and the toxoplasma gondii ROP19DNA vaccine is obtained. According to the DNA vaccine for preventing the toxoplasmosis of the humans or the animals, active immunization is conducted on BALB/c mice through the DNA vaccine, the immunogenicity of the vaccine is evaluated by determining cells and humoral immunity indexes of immunized mice, and the immunoprotectivity of the vaccine is estimated by counting the number of cysts in brains of the mice and the survival rate of the mice after attack experiments of toxoplasma gondii are conducted. By means of the DNA vaccine for preventing the toxoplasmosis of the humans or the animals, humoral immunity and cellular immune responses can be effectively enhanced, the formation rate of the brain cysts of the immune mice attacked by a toxoplasma gondii PRU strain (II type) is effectively decreased, and the survival time of the mice attacked by a toxoplasma gondii RH stain (I type) is prolonged.

The invention discloses a toxoplasma gondii fluorogenic quantitative PCR specific primer, a kit and a detecting method of the toxoplasma gondii fluorogenic quantitative PCR specific primer. The kit comprises the toxoplasma gondii fluorogenic quantitative PCR specific primer, a DNA extracting solution, a fluorogenic quantitative PCR reacting solution, a quality-controlling reacting solution, Spin Columns CB3 and Collection Tubes 2ml. According to the kit, GRA7 gene is utilized as a genetic marker, and the specific primer is used for optimizing PCR reacting system conditions like reagent concentration and temperature. Thus, the kit can quickly, specifically and flexibly detect whether animals are infected by toxoplasmosis, is convenient to operate and can be applied to diagnosis of various kinds of animal toxoplasmosis.

The invention relates to a Toxoplasma gondii rapid detection kit and a preparation method thereof. The kit is based on the molecular biology and the nucleoside triphosphate hydrolase (NTPase) gene with high conservation of Toxoplasma gondii to adopt the loop-mediated isothermal amplification (LAMP) method to perform the rapid detection of Toxoplasma gondii. The kit contains LAMP reaction solution, primer, Bst DNA polymerase, color reagent, standard positive template and dd H2O. The kit of the invention is characterized by high sensitivity and specificity, rapid reaction, simple operation and the like, does not require special instrument and equipment and solves the defects of the prior art such as long detection time of toxoplasmosis, large workload and complicated operation. The kit of the invention can be used to detect whether a clinical sample contains Toxoplasma gondii and used in the early diagnosis and the molecular epidemiological study of toxoplasmosis.

The invention discloses a toxoplasma gondii dense granular protein GRA1. A nucleotide sequence for encoding the protein is shown as SEQ ID NO:1. The invention further discloses an application of the dense granular protein GRA1 to the preparation of an enzyme-linked immunoassay detecting kit for treating toxoplasmosis and an enzyme-linked immunoassay method for detecting a sheep toxoplasma gondii IgG antibody. The method has the advantages such as high sensitivity, strong specificity, good accuracy as well as high speed, simplicity and convenience when being used for detecting the toxoplasmosis.

The present invention relates to a method for preparing a cyclic peptide with antiparasite activity and anticancer activity. The invention also relates to this peptide as an antiparasite agent, for example in the treatment of toxoplasmosis and as an anticancer agent. The invention also relates to the use of this cyclic peptide for treating organs ex vivo before transplantation.